Treatment Effects on Development of Chemotherapy-Induced Peripheral Neuropathy in Patients With Cancer
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Anatomic Stage III Breast Cancer AJCC v8
- Anatomic Stage IB Breast Cancer AJCC v8
- Anatomic Stage I Breast Cancer AJCC v8
- Anatomic Stage IA Breast Cancer AJCC v8
- Anatomic Stage II Breast Cancer AJCC v8
- Stage IIA Lung Cancer AJCC v8
- Stage I Lung Cancer AJCC v8
- Anatomic Stage IIA Breast Cancer AJCC v8
- Anatomic Stage IIB Breast Cancer AJCC v8
- Prognostic Stage II Breast Cancer AJCC v8
- Prognostic Stage IA Breast Cancer AJCC v8
- Stage III Ovarian Cancer AJCC v8
- Stage IIIB Lung Cancer AJCC v8
- Stage IIIB Ovarian Cancer AJCC v8
- Stage IIA Ovarian Cancer AJCC v8
- Stage IA1 Lung Cancer AJCC v8
- Stage II Ovarian Cancer AJCC v8
- Prognostic Stage IIA Breast Cancer AJCC v8
- Prognostic Stage IIIA Breast Cancer AJCC v8
- Stage IIIA Lung Cancer AJCC v8
- Stage IIIC Ovarian Cancer AJCC v8
- Prognostic Stage I Breast Cancer AJCC v8
- Prognostic Stage IB Breast Cancer AJCC v8
- Stage III Lung Cancer AJCC v8
- Stage I Ovarian Cancer AJCC v8
- Anatomic Stage IIIA Breast Cancer AJCC v8
- Stage II Lung Cancer AJCC v8
- Prognostic Stage IIIB Breast Cancer AJCC v8
- Stage IC Ovarian Cancer AJCC v8
- Stage IIIA2 Ovarian Cancer AJCC v8
- Stage IIB Lung Cancer AJCC v8
- Anatomic Stage IIIB Breast Cancer AJCC v8
- Prognostic Stage III Breast Cancer AJCC v8
- Stage IIIA Ovarian Cancer AJCC v8
- Stage IIIA1 Ovarian Cancer AJCC v8
- Stage IA Ovarian Cancer AJCC v8
- Stage IIB Ovarian Cancer AJCC v8
- Stage IIIC Lung Cancer AJCC v8
- Stage IB Lung Cancer AJCC v8
- Stage IA2 Lung Cancer AJCC v8
- Prognostic Stage IIIC Breast Cancer AJCC v8
- Anatomic Stage IIIC Breast Cancer AJCC v8
- Stage IB Ovarian Cancer AJCC v8
- Prognostic Stage IIB Breast Cancer AJCC v8
- Lung Non-Small Cell Carcinoma
- Stage IA3 Lung Cancer AJCC v8
- Type
- Observational
- Design
- Observational Model: CohortTime Perspective: Prospective
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
PRIMARY OBJECTIVES: I. To develop and validate a clinical risk prediction model using clinical factors for the development of peripheral neuropathy in patients receiving taxane-based chemotherapy regimens. SECONDARY OBJECTIVES: I. To examine patient-reported outcomes (PROs) and objective measures of...
PRIMARY OBJECTIVES: I. To develop and validate a clinical risk prediction model using clinical factors for the development of peripheral neuropathy in patients receiving taxane-based chemotherapy regimens. SECONDARY OBJECTIVES: I. To examine patient-reported outcomes (PROs) and objective measures of chemotherapy induced peripheral neuropathy (CIPN) to better define the phenotype of peripheral neuropathy in this patient population. II. To assess the incidence of CIPN within one year in this patient population. III. To identify predictors of treatment dose reductions, delays, and discontinuations associated with CIPN symptoms in this patient population. OTHER OBJECTIVES: I. To collect serum and plasma samples for future testing for biomarker and mechanistic studies of CIPN. OUTLINE: Patients receive chemotherapy regimen per treating physician for 52 weeks in the absence of disease progression or unacceptable toxicity. Patients also complete questionnaires at weeks 4, 8, 12, 24 and 52.
Tracking Information
- NCT #
- NCT03939481
- Collaborators
- National Cancer Institute (NCI)
- Investigators
- Principal Investigator: Meghna S Trivedi Southwest Oncology Group